Upgrades/Downgrades
Updated: 28-Jul-26 09:45 ET
| Upgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Richardson Elec | RELL | Northland Capital | Market Perform » Outperform | $24 | |
| Nutrien | NTR | BNP Paribas Exane | Neutral » Outperform | $80 | |
| Magnolia Oil & Gas | MGY | Truist | Hold » Buy | $33 | |
| Lufax | LU | JP Morgan | Neutral » Overweight | $2 | |
| JBS SA | JBS | JP Morgan | Neutral » Overweight | $18 | |
| Int'l Paper | IP | JP Morgan | Neutral » Overweight | $61 | |
| Honeywell | HON | BofA Securities | Underperform » Neutral | $265 | |
| Grupo Cibest S.A. | CIB | Goldman | Neutral » Buy | $98 | |
| Gossamer Bio | GOSS | Leerink Partners | Market Perform » Outperform | $1 | |
| Solventum | SOLV | UBS | Neutral » Buy | $95 | |
| Medtronic | MDT | UBS | Neutral » Buy | $100 | |
|
|
|||||
| Downgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Coca-Cola FEMSA | KOF | HSBC Securities | Buy » Hold | $116 | |
| Eastern Bankshares | EBC | Stephens | Overweight » Equal-Weight | $24 | |
| Selective Insurance | SIGI | BMO Capital Markets | Outperform » Market Perform | $97 | |
| RXO, Inc. | RXO | TD Cowen | Hold » Sell | $19 | |
| Progyny | PGNY | Barclays | Overweight » Equal Weight | $34 | |
| Levi Strauss | LEVI | Wells Fargo | Overweight » Equal Weight | $25 | |
| Intuit | INTU | TD Cowen | Buy » Hold | $304 | |
| Fresenius Medical | FMS | BNP Paribas Exane | Neutral » Underperform | $19.90 | |
| Exxon Mobil | XOM | BofA Securities | Buy » Neutral | $158 | |
| Clorox | CLX | Jefferies | Buy » Hold | $98 | |
| Alpine Income Property Trust | PINE | Raymond James | Strong Buy » Outperform | $22 | |
| Albertsons | ACI | UBS | Buy » Neutral | $12 | |
| Visteon | VC | Wolfe Research | Outperform » Peer Perform | ||
| Spyre Therapeutics | SYRE | Wolfe Research | Outperform » Peer Perform | ||
| PROCEPT BioRobotics | PRCT | UBS | Buy » Neutral | $20 | |
| MapLight Therapeutics | MPLT | Morgan Stanley | Overweight » Equal-Weight | $21 | |
| Bank of Marin | BMRC | Brean Capital | Buy » Neutral | $33 | |
| Capricor Therapeutics | CAPR | Alliance Global Partners | Buy » Neutral | $7 | |
|
|
|||||
| Coverage Initiated | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| MiniMed | MMED | UBS | Buy | $25 | |
| Benitec Biopharma | BNTC | Wedbush | Outperform | $16 | |
| Alphatec | ATEC | UBS | Buy | $15 | |
| Globus Medical | GMED | UBS | Neutral | $82 | |
| Bausch + Lomb | BLCO | UBS | Buy | $21 | |
| Cooper | COO | UBS | Neutral | $75 | |
| STAAR Surgical | STAA | UBS | Sell | $20 | |
| Tenax Therapeutics | TENX | Canaccord Genuity | Buy | $35 | |
| Kodiak Gas Services | KGS | Piper Sandler | Overweight | $78 | |
| H & R Block | HRB | Stephens | Equal-Weight | $47 | |
| Faeth Therapeutics | FTH | Oppenheimer | Outperform | $60 | |
| CrowdStrike | CRWD | Loop Capital | Buy | $230 | |
| Zimmer Biomet | ZBH | UBS | Buy | $115 | |
| TransMedics Group | TMDX | UBS | Neutral | $80 | |
| Teleflex | TFX | UBS | Neutral | $145 | |
| Steris | STE | UBS | Buy | $275 | |
| SI-BONE | SIBN | UBS | Buy | $24 | |
| Shoulder Innovations | SI | UBS | Buy | $27 | |
| Rapport Therapeutics | RAPP | William Blair | Outperform | ||
| Intuitive Surgical | ISRG | UBS | Buy | $500 | |
| Integra | IART | UBS | Neutral | $19 | |
| GXO Logistics | GXO | Wells Fargo | Overweight | ||
| Glaukos | GKOS | UBS | Neutral | ||
| Edwards Lifesciences | EW | UBS | Buy | $110 | |
| Becton Dickinson | BDX | UBS | Buy | $19 | |
|
|
|||||
| Coverage Resumed | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Sight Sciences | SGHT | UBS | Buy | $7 | |
| Tandem Diabetes Care | TNDM | UBS | Neutral | $18 | |
| Beta Bionics | BBNX | UBS | Buy | $22 | |
| Insulet | PODD | UBS | Neutral | $174 | |
| Stryker | SYK | UBS | Buy | $400 | |
| Inspire Medical Systems | INSP | UBS | Sell | $39 | |
|
|
|||||
| Coverage Reiterated/Price Tgt Changed* | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Tesla | TSLA | RBC Capital Mkts | Outperform | $500 » $480 | |
|
|
|||||
| (a) Brokerage firm initiating coverage participated in underwriting the recent IPO. |
| (b) Brokerage firm resumes coverage. |
| (c) Brokerage firm participated in the secondary offering. |
| * This list of reiterations/target changes is not comprehensive. |